Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use STEQEYMA safely and effectively. See full prescribing information for STEQEYMA. STEQEYMA (ustekinumab-stba) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2024 STEQEYMA (ustekinumab-stba) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of STEQEYMA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s)), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to STELARA® (ustekinumab).
Medication labelWhy this: Advisory · dailymed-prescription
STEQEYMA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. STEQEYMA is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. STEQEYMA is indicated for the treatment of adult patients with moderately to severely active Crohn's disease. STEQEYMA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
- generic_name
- ustekinumab-stba
- product_names
- ustekinumab-stba
- ndc
- 72606-027, 72606-027-01, 72606-028, 72606-028-01, 72606-029, 72606-029-01, 72606-060, 72606-060-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en